The Steno-2 trial reported that a multifactorial cardiovascular risk intervention (including ACE inhibition) appeared to reduce the prevalence of autonomic dysfunction by 63% [15]. This evidence concerns the gene ACE and Abnormal autonomic nervous system physiology.